ERBB2 and breast carcinoma: Similarly, NK-92 cells harboring an EBV EBNA3C-specific CAR lysed peptide-pulsed B-cell lymphoblastic cells more efficiently than CD16-engineered NK-92 in the presence of an anti-EBNA3C-Fc fusion protein (78) and NK-92 cells expressing a trastuzumab-based ErbB2-specific CAR with an FcεRIγ signaling domain displayed more enhanced cytotoxicity against breast carcinoma cells than NK-92 harboring a CD16-FcεRIγ hybrid receptor in combination with trastuzumab antibody (58).